Aspire Biopharma Holdings (ASBP) Profit After Tax (2021 - 2026)
Aspire Biopharma Holdings (ASBP) posted quarterly Profit After Tax of -$3.2 million for Q1 2026, up 79.78% year-over-year from -$1.8 million in Q1 2025, and up 31.54% quarter-over-quarter from -$4.7 million in Q4 2025.
Aspire Biopharma Holdings (ASBP) Profit After Tax (2021 - 2026) Analysis & Trends
Aspire Biopharma Holdings (ASBP) has reported Profit After Tax for 6 consecutive years, with -$3.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Profit After Tax rose 79.78% year-over-year to -$3.2 million; the TTM figure through Mar 2026 stood at -$11.8 million (up 30.89% YoY), while the FY2025 annual figure was -$24.5 million, down 1768.95% from the prior year.
- Profit After Tax advanced to -$3.2 million in Q1 2026 per ASBP's latest filing, from -$4.7 million in the prior quarter.
- Across five years, Profit After Tax topped out at $2.9 million in Q1 2023 and bottomed at -$15.9 million in Q1 2025.
- Historically, Profit After Tax has averaged -$1.2 million across 5 years, with a median of -$150913.0 in 2023.
- Annual changes were most pronounced in 2022 — Profit After Tax soared 295484.64% — and 2025, when it slumped 6801.9%.
- Aspire Biopharma Holdings' Profit After Tax stood at $2.2 million in 2022, then sank by 106.77% to -$150913.0 in 2023, then sank by 407.39% to -$765710.0 in 2024, then plunged by 514.82% to -$4.7 million in 2025, then jumped by 31.54% to -$3.2 million in 2026.
- Business Quant data shows ASBP's Profit After Tax at -$3.2 million in Q1 2026, -$4.7 million in Q4 2025, and -$1.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 472.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -355.03 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -16.62 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Aspire Biopharma Holdings | 8.30 Mn | -3.86 Mn | -30,086.00 | -1.27 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1.27 Mn |
| Mar 31, 2026 | -3.22 Mn |
| Dec 31, 2025 | -4.71 Mn |
| Sep 30, 2025 | -1.85 Mn |
| Jun 30, 2025 | -1.98 Mn |
| Mar 31, 2025 | -15.94 Mn |
| Dec 31, 2024 | -765,710.00 |
| Sep 30, 2024 | -216,269.00 |
| Jun 30, 2024 | -96,923.00 |
| Mar 31, 2024 | -230,970.00 |
| Dec 31, 2023 | -150,913.00 |
| Sep 30, 2023 | -69,258.00 |
| Jun 30, 2023 | 1.81 Mn |
| Mar 31, 2023 | 2.87 Mn |
| Dec 31, 2022 | 2.23 Mn |
| Sep 30, 2022 | 1.08 Mn |
| Jun 30, 2022 | 120,693.00 |
| Mar 31, 2022 | -87,826.00 |
| Dec 31, 2021 | -755.00 |
| Sep 30, 2021 | -15,310.00 |